Recent research suggests that the composition of an individual’s gut and oral microbiome can significantly influence the severity of their reaction to peanut allergies. This discovery could explain why some individuals experience mild symptoms while others suffer life-threatening anaphylaxis, offering potential new strategies for managing this widespread and dangerous condition.
The Role of the Microbiome in Allergic Response
Peanut allergy develops when the immune system misidentifies peanut proteins as harmful, triggering an excessive antibody response and inflammation. This can range from mild discomfort to anaphylaxis—a severe, potentially fatal reaction involving breathing difficulties and a sharp drop in body temperature. Researchers have long suspected that the diverse microbial ecosystems within our bodies, particularly in the gut and mouth, play a crucial role in regulating this immune response.
Mouse Studies Reveal Key Bacterial Strain
A study led by Rodrigo Jiménez-Saiz at the Autonomous University of Madrid investigated this connection using mice. Researchers compared three groups: mice raised without any gut bacteria (germ-free), mice with minimal microbial diversity, and mice with a typical, healthy microbiome. When exposed to peanuts, mice with limited or no gut bacteria exhibited higher levels of peanut allergy-related proteins (Ara h 1 and Ara h 2) in their small intestines.
The key difference? The presence of Rothia bacteria, especially the strain Rothia R3, which breaks down peanuts in the gut. Mice implanted with Rothia R3 before peanut exposure showed milder anaphylactic symptoms—a smaller drop in body temperature and lower levels of a critical immune molecule (MMCP-1) compared to those without the bacteria. This indicates that Rothia R3 appears to mitigate the severity of allergic reactions.
Human Data Corroborates Findings
The link between gut bacteria and allergy severity wasn’t limited to mice. In a separate study involving 19 people with peanut allergies, those who tolerated peanuts better had significantly higher levels of Rothia bacteria in their saliva. This suggests that the presence of these bacteria in both the gut and mouth influences anaphylaxis risk.
Future Implications: Probiotic Treatment
Researchers are now exploring whether Rothia -based probiotics could reduce the severity of anaphylaxis in humans. According to Mohamed Shamji at Imperial College London, “The need for something like this is huge,” particularly to ease fears around accidental exposure and improve oral immunotherapy—a treatment involving gradual allergen exposure. Clinical trials are planned to test whether administering Rothia probiotics before peanut exposure can lessen allergic reactions.
This research highlights the critical interplay between the microbiome and immune function, opening doors to novel therapeutic interventions for allergies.
If confirmed in human trials, Rothia probiotics could offer a practical way to manage peanut allergy risk and improve the quality of life for millions.
